X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MC16
Therapeutic Area: Genetic Disease Product Name: MC16
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2021
Details:
MC16 is unique in that it is designed to be a gene-mutation agnostic treatment with the potential to treat all forms of RP.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rAAV2tYF-CB-hRS1
Therapeutic Area: Genetic Disease Product Name: rAAV2tYF-CB-hRS1
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TeamedOn
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 13, 2021
Details:
Under the terms of the agreement, AGTC will provide TeamedOn with the clinical trial material, pre-clinical and clinical data generated for the development of AGTC’s investigational intravitreal gene therapy candidate, rAAV2tYF-CB-hRS1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $239.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2021
Details:
Dewpoint Therapeutics and Pfizer will collaborate for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
